Novo Nordisk and WeightWatchers Partnership, Plus $299 Wegovy Offer

Novo Nordisk will increase Wegovy access through a WeightWatchers partnership and a new self-pay opportunity, according to a news release published today. Beginning July 1, 2025, obesity patients will be able to purchase any dose of Wegovy (semaglutide) for $299. Patients can access this one-time offer on Wegovy.com and then take the code to a pharmacy of their choice. Patients can have their prescription filled through CenterWell Pharmacy, now associated with Novo Nordisk and WeightWatchers. Prescriptions will also be available through NovoCare Pharmacy, Ro and LifeMD.

Wegovy’s current one-time price of $199 for self-paying patients ends June 30, 2025. Patients who redeemed this previous offer between May 22 and June 30, 2025, will also be eligible for the new $299 offer on one prescription fill between July 1 and July 31. For subsequent months, Wegovy will cost $499 for self-paying patients.

“Novo Nordisk continues to build on existing efforts and identify new options that help all patients, regardless of where they choose to access authentic, FDA-approved Wegovy as part of our relentless focus on patient safety," the news release says.

This announcement follows the June 23, 2025, termination of the relationship between Novo Nordisk and Hims & Hers Health, an American telehealth company founded in 2017. Novo Nordisk alleges Hims & Hers Health continued to sell compounded semaglutide even after the FDA resolved the Wegovy shortage in April, according to a news release. Novo Nordisk cited manufacturing and safety concerns of the compounded semaglutide, which is manufactured in China by a large share of suppliers that were never inspected by the FDA, according to a report from the Brookings Institution.

“Novo Nordisk has already filed nearly 120 lawsuits across 34 states against entities who unlawfully market or sell knockoff drugs,” the news release said.

Wegovy was approved by the FDA to treat obesity in adults in June 2021, in combination with a reduced-calorie diet and increased physical activity. A second approval followed in December 2022 for adolescents ages 12 and older. It is available as a weekly 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg single-dose injection pen. While its list price is currently $1,349, the company says that 90% of patients have a co-pay of $0 to $25 per month.

Obesity is a chronic condition affecting approximately 40% of people in the United States aged 20 and older, accounting for nearly $173 billion in health expenditures in 2019, according to a Centers for Disease Control and Prevention estimate.